How to improve R&D productivity: the pharmaceutical industry's grand challenge

Can the pharmaceutical industry reduce attrition rates?

2004 • 3,946 citations

The druggable genome

2002 • 3,099 citations

Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart Disease

2006 • 2,981 citations

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

2003 • 2,802 citations

A Proof for the Queuing Formula: L = λW

1961 • 2,611 citations

The Goal: A Process of Ongoing Improvement

1984 • 1,104 citations

The truth about the drug companies: how they deceive us and what to do about it

2005 • 903 citations

PCSK9: a convertase that coordinates LDL catabolism

2008 • 608 citations

The Six Sigma Handbook: A Complete Guide for Green Belts, Black Belts, and Managers at All Levels

2014 • 578 citations

Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes

2006 • 534 citations

The cost of biopharmaceutical R&D: is biotech different?

2007 • 518 citations

The Goal: A Process of Ongoing Improvement

2005 • 475 citations

Science Business: The Promise, the Reality and the Future of Biotech

2007 • 409 citations

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

2009 • 393 citations

Science Business: The Promise, the Reality and the Future of Biotech

1969 • 351 citations

The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates

2007 • 346 citations

Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders

2007 • 332 citations

Prospects for productivity

2004 • 283 citations

The State of Innovation in Drug Development

2008 • 268 citations

A PROOF OF THE QUEUING FORMULA

1961 • 267 citations

Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances

2005 • 244 citations

The Value of Improving the Productivity of the Drug Development Process

2002 • 233 citations

Rebuilding the R&D engine in big pharma.

2008 • 232 citations

Drug discovery in jeopardy

2006 • 208 citations

The Prospects for “Personalized Medicine” in Drug Development and Drug Therapy

2007 • 175 citations

The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982?2001

2005 • 163 citations

Prescription Drug Spending Trends In The United States: Looking Beyond The Turning Point

2008 • 145 citations

Adaptive Seamless Phase II/III Designs—Background, Operational Aspects, and Examples

2006 • 133 citations

Pricing medicines: theory and practice, challenges and opportunities

2005 • 117 citations

The truth about drug companies: how they deceive us and what to do about it

2006 • 114 citations

Macro trends in pharmaceutical innovation

2005 • 109 citations

A more rational approach to new-product development.

2008 • 67 citations

Sodium channels and nociception: recent concepts and therapeutic opportunities

2007 • 56 citations

Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development

2007 • 53 citations

The Truth about Drug Companies: How They Deceive Us and What to Do about It

2006 • 47 citations

Further LDL Cholesterol Lowering Through Targeting PCSK9 for Coronary Artery Disease

2008 • 17 citations

Modeling Resource Requirements for Pharmaceutical R&D

2002 • 15 citations

Candidate Genes for Osteoporosis

2001 • 13 citations

Pharma industry performance metrics: 2007–2012E

2008 • 12 citations

Significance of the human genome sequence to drug discovery

2001 • 10 citations

Pharma industry strategic performance: 2007–2012E

2008 • 8 citations